Recurrent and/or metastatic head and neck cancer is usually incurable. Implementation of precision oncology for these patients has been limited by incomplete understanding of the molecular alterations underlying advanced disease. At the same time, the molecular profiles of many rare head and neck cancer types are unknown. These significant gaps in knowledge need to be addressed to rationally devise new therapies.
Genetic profiles of the most clinically challenging tumorsincurable, recurrent and metastatic disease-remain poorly defined. Less common cancer types have not heretofore been molecularly profiled. Here, we describe our multidisciplinary head and neck cancer team's implementation of a precision oncology approach, review therapeutic successes and limitations for patients, and analyze sequencing data to glean new insights into the alterations that define recurrent and metastatic head and neck cancer.
Methods
The MSK-IMPACT (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets) assay is a targeted next-generation sequencing (NGS) assay approved through Clinical Laboratory Improvement Amendments. 11 The assay is optimized for DNA from formalin-fixed, paraffinembedded samples, and targets single nucleotide variants, indels, and structural variants in 410 genes functionally relevant to cancer or clinically actionable targets (eTable 1 in Supplement 2), and genome-wide copy number. 12, 13 After receiving institutional review board approval from the Memorial Sloan Kettering Cancer Center, we reviewed patients treated by our multidisciplinary head and neck oncology team whose tumors were sequenced after informed written consent to an institutional review board-approved protocol (NCT01775072). Of 224 patients enrolled, 151 with minimum 6-month follow-up, whose tumors were sequenced between January 2014 and July 2015, were included. Treatment(s) initiated after NGS were considered guided by molecular data if results led to, or justified continuation with, specific treatments. Molecular alterations were classified by evidence indicating standard or investigational therapies (eTable 2 in Supplement 2).
Copy number analyses with FACETS 14 were performed to identify whole-genome duplication, 3p deletion (eFigures 1 and 2i nSupplement 1), and subclonal population structure.
Mutational signatures (APOBEC, tobacco, ultraviolet light carcinogenesis) were analyzed using definitions previously described.
15,16
Somatic alterations in HNSCC were examined using a support vector machine algorithm to classify human papillomavirus (HPV) status, and using enrichment analysis for comparison to primary tumors in the The Cancer Genome Atlas (TCGA) cohort. 3 Germline sequencing from matched normal blood was analyzed using a previously described pipeline. 13 Additional technical details of the assay, variant calling, support vector machine algorithm, bioinformatic and biostatistical analyses are in the eAppendix in Supplement 1.
Results
MSK-IMPACT was used to sequence 151 head and neck tumors, including 53 HNSCC, 56 salivary carcinomas, 27 cutaneous carcinomas, 8 nasopharyngeal carcinomas, 3 neuroendocrine carcinomas, 2 odontogenic carcinomas, and 2 olfactory neuroblastomas (eFigure 11 in Supplement 1), in 95 men and 56 women; 66 patients had locoregional recurrence, 106 had distant metastases, and 6 had locally advanced tumors that were surgically unresectable. Clinical data are summarized in eTable 3 in Supplement 2. Median (range) depth of sequencing was 600 × (82 × −1165 ×). Survival and genomic data are summarized in Figure 1 and eFigures 12 and 13 in Supplement 1.
Actionable Alterations
There are no standard-of-care biomarkers in head and neck cancer, but 28 of 135 patients (21%) with tumors harboring alterations had findings with potential investigational implications-7 patients (5%) with a US Food and Drug Administration (FDA)-approved biomarker and drug in another indication, and 21 patients (16%) with clinical evidence linking the alteration to drug response ( Figure 1 ) (eTable 2 in Supplement 2). Ultimately, next-generation sequencing data guided therapy in 21 of 151 patients (14%).
Landscape of HNSCC
The most frequent single nucleotide variants and copy number variants in HNSCC are depicted in Figure 2 and eTable 4
Key Points
Question Can clinical implementation of next-generation sequencing of tumors help guide treatment and expand our understanding of the biology of advanced head and neck cancer?
Findings Molecular profiling of advanced (nearly all recurrent and metastatic) head and neck cancers was able to identify actionable alterations and guide treatment in a portion of patients, refine diagnoses in certain rare cancers, and discover unique genetic findings that are enriched in advanced cancers.
Meaning Implementation of precision oncology is beginning to guide treatment and improve our knowledge of molecular alterations relevant to advanced, treatment-resistant head and neck cancers.
The promoter region of TERT harbored mutations in 16 of 30 HPV-negative tumors (53%) (Figure 3) . In this recurrent and metastatic population, mutations in the TERT promoter were significantly more frequent than rates reported in primary HPVnegative HNSCCs 18 (12 of 70 [17%]) (odds ratio (OR), 5.5; P < .001), indicating enrichment for this mutation in advanced cancers, although we note that deep sequencing may be more sensitive for single nucleotide variants. Remarkably, 10 of 11 (91%) HPV-negative tongue SCCs had TERT muta- positive HNSCC, consistent with the ability of the E6 oncoprotein to activate telomerase. 20 Therefore, TERT mutation and HPV infection may represent parallel mechanisms of telomerase activation in HNSCC. Four tumors had mutations in mismatch repair genes, including 1 truncating mutation in MLH1 (in the highly mutated HPV-positive case) and missense mutations in MSH2, MSH6, and POLD1 (HPV-negative cases). The average mutation count in these tumors was significantly elevated (17.3 vs 4.5; P < .001).
After NGS, 17 of 53 patients with HNSCC (32%) were enrolled in clinical trials. Treatment was guided by molecular data in 13 patients (25%). In 7 patients (13%), NGS nominated targeted therapies, similar to the rate in another recent HNSCC precision oncology study (10%). 21 Four patients with alterations in PIK3CA or PTEN were treated on PI3K inhibitor trials, 1 HRAS mutation on a farnesyl transferase inhibitor trial, 1 MAPK1 mutation with an ERK inhibitor on a single-patient IND (Investigational New Drug) application, and 1 SMARCB1 deletion on an EZH2 inhibitor trial. In 6 patients (12%), the lack of actionable alterations on We used FACETS to infer levels of intratumor heterogeneity.
14 In multivariable analyses, HPV-positive tumors had fewer subclonal populations (P = .03). Recurrent and metastatic sites trended toward having more subclonal mutations than primary sites (P = .08) (eTables 6 and 7 in the Supplement 2).
Alterations Enriched in Recurrent and Metastatic HPV-Positive HNSCC
The vast majority of HPV-positive HNSCCs are cured with standard therapy. 22 The genetic alterations in the minority of these tumors developing recurrence and/or metastasis are largely undefined. We examined alterations that were enriched in recurrent and metastatic HPV-positive HNSCC sequenced with MSK-IMPACT, in comparison to primary HPV-positive tumors sequenced by TCGA. 3 These 2 cohorts had similar clinical and demographic profiles, including smoking history (50% vs 61%; P = .57). We first examined variant profiles and determined the degree of similarity between each advanced HPV-positive tumor sequenced with MSK-IMPACT compared with HPVpositive and HPV-negative primary tumors sequenced by TCGA. We used a support vector machine algorithm to categorize tumors as more similar to HPV-positive or HPVnegative profiles based on mutations and copy number variants. The classifier was first trained and cross-validated in the TCGA cohort, then applied to 53 sequenced MSK-IMPACT samples in 51 patients with known HPV status. The classifier correctly categorized 29 of 31 (91%) HPV-negative MSK-IMPACT cases, but only 12 of 21 (57%) HPV-positive cases (P = .007) (eFigure 15 in Supplement 1). The classifier had significantly higher confidence probabilities for HPV-negative tumors (P =4. We examined enrichment for specific genetic alterations, focusing on the most frequent: whole-genome duplication, 3p deletion, TP53 mutation, and PIK3CA mutation. To allow for potential differences between platforms, we determined enrichment by comparing HPV-negative:HPV-positive ORs between data sets ( Figure 4A ) (eTable 8 in Supplement 2). In the recurrent and metastatic HPV-positive tumors, there was significant enrichment for whole-genome duplication (6.7-fold; P = .024), 3p deletion (9.1-fold; P = .002), and 3p deletion-TP53 mutation (7.6-fold; P = .03). tumors. The degree of chromosomal instability in TP53 or RB1 mutated HPV-positive tumors was significantly higher than in TP53/RB1 wildtype tumors (P = .009). This suggests that complete inactivation of p53 or RB has functional sequelae beyond those resulting from incomplete degradation by E6/E7 ( Figure 4B ).
Mutational Signatures in HNSCC
The tobacco signature was strongest in current smokers and was most evident in laryngeal cancers, similar to findings in TCGA exome data 26 (eFigure 5 in Supplement 1). There was no difference in APOBEC scores between HPV-positive and HPVnegative tumors (1.68 vs 1.36; P = .29), in contrast to data from primary tumors, where the APOBEC signature is associated with HPV-positivity. 27 This is consistent with the overall trend of molecular differences between HPV-positive and HPVnegative disease being attenuated in advanced cancers. The tumors with the strongest APOBEC signatures were either sinonasal or oropharynx primaries, mostly HPV-positive (eFigure 5 in Supplement 1).
Adenoid Cystic Carcinomas
Of 36 recurrent and metastatic ACCs, mutational load (mean, 2.3) and fraction of copy number-altered genome (mean, 0.12) were low. nominating these drugs as potentially active in NOTCH1-mutated ACCs. TERT promoter mutations were also identified in 5 ACCs (14%). TERT promoter mutations have not been previously identified in salivary cancers (eFigure 17 in Supplement 1 and eTable 4 in Supplement 2). Twenty (56%) patients with ACCs were enrolled on clinical trials. In 4 patients (11%), protocol selection was guided by NGS: 1 patient with FGFR3 mutation was treated with an FGFR inhibitor, 1 patient with a PIK3CA mutation and 1 patient with a PIK3R1 mutation were treated with a PI3K inhibitor, and 1 patient with MDM2 amplification was treated with an MDM2 inhibitor. Although not guided by NGS, 4 patients treated with the multikinase inhibitor regorafenib were subsequently found to have PDGFRA/KDR/KIT amplification, justifying the appropriateness of this protocol.
Other Salivary Cancers
There were 20 advanced salivary cancers of other histologies: 11 salivary duct carcinomas, 2 acinic cell carcinomas, 2 mammary analog secretory carcinomas (MASC), 2 mucoepidermoid carcinomas, 2 salivary adenocarcinomas, and 1 epithelial-myoepithelial carcinoma ( Figure 6 ) (eTable 4 in Supplement 2).
Salivary duct carcinomas harbored numerous potentially actionable alterations (including PIK3CA, HRAS, ERBB2, and AR) and several interesting structural variants in NF1 and ROS1 (eTable 2) (eFigure 7 in Supplement 1). One mucoepidermoid tumor with an HRAS G13V mutation was enrolled on a farnesyl transferase inhibitor trial.
One tumor was initially diagnosed as acinic cell carcinoma. Sequencing identified an ETV6-NTRK3 fusion (eFigur e8inSupplement 1), changing the diagnosis to MASC. 30 The patient was then enrolled on a TRK inhibitor basket study, with a clinical near-complete response.
31 A second acinic cell carcinoma was rediagnosed as MASC and enrolled on a TRK inhibitor basket study, also with a similar major response.
Cutaneous Carcinomas
Twenty-seven advanced nonmelanoma skin carcinomas of the head and neck were sequenced: 21 squamous, 2 skin adnexal, and 4 basal cell carcinomas (BCCs) ( Figure 7 ) (eFigu r e1 8i nSupplement 1 and eTable 4 in Supplement 2). A predominating UV light mutational signature was evident in 18 of 21 (86%) cutaneous SCCs and was associated with higher average mutation counts than the cutaneous SCCs lacking a UV light mutational signature (37.9 mutations vs 4.3 mutations; P = .008). Deletion of 3p in combination with TP53 mutation is a strong negative prognostic factor in mucosal HNSCC, 32 but these co-occurring alterations have not been described in cutaneous SCC. We found 3p deletion and TP53 mutation in 6 of 19 cases (32%). Three of 4 advanced BCCs exhibited the UV light mutational signature, including 1 hypermutated tumor with 122 mutations. In this case, the finding of high mutational load led to a decision to treat with immunotherapy.
One BCC lacking the UV light signature had only 2 nonsynonymous mutations: a patient who had scalp irradiation in childhood. Three of four BCCs responded initially to hedgehog pathway inhibitors (prior to NGS) and were subsequently confirmed to have PTCH1 mutations.
Nasopharyngeal Carcinomas
Eight recurrent and metastatic nasopharyngeal carcinomas were sequenced (eFigure 19 in Supplement 1 and eTable 4 in Supplement 2). Four patients with nasopharyngeal carcinoma (50%) were enrolled on clinical trials, of which one (13%) was NGS-guided: a PIK3CA mutation led to enrollment on a PI3K inhibitor trial.
Odontogenic Carcinomas
Two odontogenic carcinomas were profiled. Unexpectedly, EWSR1 gene fusions were found in both (eFigure 9 in Supplement 1). One case, initially diagnosed as ameloblastic carcinoma, had an EWSR1-FLI1 fusion, confirmed with a polymerase chain reaction assay. Fluorescence in situ hybridization analysis performed earlier had not identified rearrangement of EWSR1, indicating the superior sensitivity of NGS in this case. This changed the diagnosis to Ewing sarcoma with epithelial dif-ferentiation and ameloblastic morphology. This information was used to guide chemotherapy with a sarcoma regimen.
The second case was a metastatic clear cell odontogenic carcinoma of the maxilla, with an EWSR1-ATF1 fusion, which has been seen in clear cell sarcomas and hyalinizing clear cell carcinoma of salivary glands, but not in (morphologically similar) odontogenic tumors.
Other Rare Cancers
The findings in 2 olfactory neuroblastomas and 3 head and neck neuroendocrine carcinomas are detailed in eTable 4 in Supplement 2.
Germline Analysis
One HNSCC patient had a germline heterozygous deletion in FANCA (eFigure 10 in Supplement 1) and a tumor with a somatic FANCA stopgain mutation. While homozygous loss of FANCA in the germline causes Fanconi anemia, this double-hit affecting FANCA is an interesting finding in HNSCC, 33 similar to a report in a prostate cancer, where it conferred sensitivity to cisplatin.
34
The ability of NGS to profile both somatic and germline alterations is an additional source of potentially actionable data. Complete genomic and clinical data from this study are available in searchable form at http://www.cbioportal.org /study?id=hnc_mskcc_2016. 
Discussion
Critical gaps in knowledge must be addressed to rationally devise new therapies for head and neck cancers. To date, genomics studies have been limited to cohorts of primary tumors. The molecular landscape of the most clinically challenging tumorstreatment-resistant, recurrent and metastatic disease-has not been defined. Furthermore, many uncommon cancer types have not been molecularly profiled.
Here, we review our implementation of precision oncology for patients with advanced head and neck cancers. This effort has been useful in 3 respects: (1) illuminating the unique molecular landscape of advanced or understudied cancers; (2) refining diagnoses of rare cancers; and (3) guiding treatment based on molecular alterations.
In the initial 2 years of this approach, NGS guided therapy in 14% of patients (25% of HNSCC patients). A major limitation has been the low frequency (21%) of targetable alterations. This underscores the importance of profiling these tumors, and the potential benefits of basket studies for diseases such as head and neck cancer. In several cases, such as the enrollment of metastatic MASC tumors on TRK inhibitor trials, NGS facilitated dramatic therapeutic responses.
Focused analyses of recurrent and metastatic tumors can provide valuable biologic insights, identifying alterations that are associated with advanced cancers. 35 For example, we identified a high rate of activating NOTCH1 mutations in meta- static ACC. We also identified genetic alterations defining recurrent and metastatic HPV-positive cancers: many tumors had genetic profiles closer to HPV-negative tumors, a finding that has potential significance to current studies of targeted therapies and chemoradiotherapy deintensification in this population. An important caveat is that these findings are based on a small cohort, and when comparing results to other data sets, it is possible that differences in patient characteristics, prior therapy, sequencing or analytic methodologies may contribute to differences observed. These results require further confirmation. Many head and neck cancers are understudied due to their rarity. We report the first molecular data in mucoepidermoid carcinomas, acinic cell carcinomas, epithelialmyoepithelial carcinomas, MASC, salivary adenocarcinoma, skin adnexal carcinomas, odontogenic carcinomas, and head and neck neuroendocrine carcinomas. While sample sizes were too limited to draw broad conclusions, many potentially actionable findings were identified and several uncommon diagnoses refined.
Finally, this analysis demonstrated the potential of targeted NGS to measure intratumor heterogeneity and identify certain mutational signatures: those of carcinogenesis driven by UV light, tobacco, APOBEC, and mismatch repair deficiency. 15, 36, 37 Emerging data implicate each of these features as potential predictive biomarkers for immunotherapy: ITH, mutational load, and the tobacco and UV light mutational signatures have each been associated with response to immune checkpoint inhibitors in lung, skin, and colorectal cancers.
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Conclusions
To advance precision head and neck oncology, a necessary first step is describing the complete catalog of molecular alterations in incurable and rare cancers. As demonstrated here, the molecular profile of recurrent and metastatic tumors is quite distinct from primary tumors. In these understudied diseases, no single institution will be able to profile a large number of patients. Pooling genomic data will be critical to devising rational therapies. Finally, a major therapeutic limitation in head and neck cancer has been the lack of matched trial options. This shows the value of basket studies, which accounted for half of clinical trial enrollments in this cohort. As understanding of molecular drivers and biomarkers expands, we anticipate the clinical value added by routine NGS will continue to increase. The majority of patients have recurrent or metastatic disease but patients are otherwise unselected. Since 2014, over 9,000 solid tumors have been profiled using MSK-IMPACT.
We reviewed all patients treated by the MSK multidisciplinary head and neck oncology team, whose tumors were sequenced with MSK-IMPACT in the context of an Institutional Review Board (IRB)-approved study (NCT01775072). Of 224 patients enrolled, 151 with a minimum of 6 month clinical followup, whose tumors were sequenced between January 2014 and July 2015, were included. This analysis was approved by the MSK IRB. Correlative clinical data are recorded prospectively in an IRBapproved database. Human papillomavirus (HPV) status was determined by p16 immunohistochemistry and HPV in situ hybridization as part of routine care. Treatment(s) initiated after ordering NGS were considered to be guided by molecular data if results led to, or justified continuation with, a specific treatment.
Sequencing platform and variant calling
MSK-IMPACT is optimized for DNA extracted from low-input formalin-fixed, paraffin embedded (FFPE) samples. The assay is designed to detect single nucleotide variants (SNVs), indels, copy number variants (CNVs) and structural variants in genes that are functionally relevant to cancer and/or clinically actionable targets. The current assay uses hybrid capture technology (Nimblegen SeqCap EZ library custom oligo) to perform deep (>200x) sequencing (Illumina HiSeq 2500) of all 5781 exons and selected introns of 410 cancer genes, including canonical and selected non-canonical transcripts, the TERT promoter region, and 33 introns of 14 rearranged genes (eTable 1). The panel includes 1042 tiling probes covering single nucleotide polymorphisms (SNPs), allowing genotyping to ensure tumor-normal matching, identify contaminating DNA, and serve as a low-density SNP array for CNV analysis. MSK-IMPACT has been extensively validated. Specific details of panel design, capture protocol, sequencing, quality control, read alignment, and variant calling have been described 2, 3 . Molecular alterations were classified according to MSK levels of evidence that support standard or investigational therapeutic indications (eTable 2).
Bioinformatic analyses
Additional copy number analyses were performed using FACETS 4 , which performs segmentation of total and allelic copy ratio, and estimates allele-specific copy number, in targeted capture sequencing data. We used FACETS to identify whole genome duplication (WGD) and deletion of 3p in SCC (eFigures 1-2) . eFigure 1.
HNSCC tumor with single copy loss of 3p and single copy gain of 3q eFigure 1. Analysis of whole-genome copy number via targeted capture next-generation sequencing. The MSK-IMPACT platform includes exonic and intronic coverage of selected genes as well as tiling probes across the genome. FACETS is used for segmentation and to determine copy number based on SNP loci read counts. The top plot represents total copy number log-ratio, corrected for library size and GC content. The middle plot represents allelic imbalance (similar to B-allele frequency), using variant allele log-odds ratio, which includes both tumor and normal allelic information. The bottom plot represents allele-specific integer copy number. The case depicted is a tumor (HPV-negative HNSCC) with single copy loss of 3p and single copy gain of 3q. 
